Genesis Therapeutics vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Genesis Therapeutics (now Genesis Molecular AI) is a biotech company applying AI to small molecule drug discovery; raised $200M Series B in 2025 led by Andreessen Horowitz, Fidelity, BlackRock, and NVIDIA;
About
Genesis Therapeutics — now operating as Genesis Molecular AI — is a clinical-stage biotechnology company founded in 2019 and headquartered in Burlingame, California. The company applies artificial intelligence and machine learning to the discovery and optimization of small molecule drug candidates, with a focus on targets that have historically been considered intractable or undruggable by conventional computational chemistry approaches. Its proprietary platform, GEMS (Genesis Exploration of Molecular Space), uses deep learning to navigate the vast chemical space of possible drug-like molecules, identifying novel compounds with high predicted potency, selectivity, and drug-like properties against disease-relevant protein targets.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.